BRIEF—Bristol Myers appoints Elizabeth Mily as EVP, strategy and business development

US Pharma major Bristol-Myers Squibb today announced that Elizabeth Mily has been appointed executive vice president, strategy and business development, effective March 30, 2020.

In this role, Ms Mily will oversee company strategy and all business development activities, including strategic partnerships, mergers and acquisitions, as well as other strategic initiatives.

“Elizabeth is an accomplished leader in investment banking and health care M&A, and I look forward to the important role she will play in sourcing external innovation to drive our vision of transforming patients’ lives through science,” said Giovanni Caforio, chairman and chief executive at Bristol-Myers Squibb.

Ms Mily will report to Mr Caforio and will be a member of the Bristol-Myers Squibb leadership team.

Ms Mily joins Bristol-Myers Squibb from Barclays, where she was the managing director and chair of the Global Lifesciences group in the global healthcare unit.

During her career she has executed over $200 billion in completed M&A advisory assignments and has advised on an extensive amount of debt, equity and equity-linked financings.

Prior to joining Barclays, Ms Mily served as head of corporate strategy and development at Thermo Fisher Scientific.

Prior to that she spent 16 years at Goldman, Sachs & Co, where she was a managing director and senior coverage officer within the Healthcare Department of the Investment Banking Division.